The company said in a news release that it will acquire Acorda’s 90,000-square-foot facility in Chelsea, Massachusetts, which provides spray drying capacity and more. The current workforce will join Catalent.
The deal complement’s Catalent’s current dry powder inhaled dose form capabilities, and it has entered into a long-term supply agreement with Acorda to continue manufacturing of its Inbrija product from the facility.
“Catalent is a premier partner to companies working on multiple forms of inhaled drug delivery, from early-stage development to commercial-scale supply,” Jonathan Arnold, president of oral and specialty delivery at Catalent, said in a prepared statement. “This acquisition complements our existing U.S.-based capabilities in metered-dose and nasal inhalation by adding an experienced team of people and a premier facility, enabling us to provide customers with extended capabilities for commercial-scale filling and packaging of dry powder inhalers.”
Completion of the transaction is scheduled for the first quarter, pending customary approvals and conditions.